Cover Image
市場調查報告書

胃接處腺癌:開發中產品分析

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257785
出版日期 內容資訊 英文 320 Pages
訂單完成後即時交付
價格
Back to Top
胃接處腺癌:開發中產品分析 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 320 Pages
簡介

所謂胃食道接合處腺癌是食道和胃食道結點的癌症。症候有失語症,體重減少,咳嗽,吞嚥疼痛,疼痛,聲音嘶啞等。因素有高齡化,體重過重(肥胖),胃食道逆流(GERD),抽煙,酒精中毒。治療方法有化療和放射線治療。

本報告提供胃接處腺癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胃接處腺癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

胃接處腺癌:企業開發中的治療藥

胃接處腺癌:大學/機關研究中的治療藥

胃接處腺癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

胃接處腺癌:企業開發中的產品

胃接處腺癌:大學/機關研究中的產品

胃接處腺癌的治療藥的開發企業

  • AB Science SA
  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cerulean Pharma, Inc.
  • 第一三共
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Imugene Limited
  • Johnson & Johnson
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Sanofi
  • 大鵬藥品工業

胃接處腺癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

胃接處腺癌:最近的開發平台趨勢

胃接處腺癌:暫停中的計劃

胃接處腺癌:開發中止的產品

胃接處腺癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8688IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.

Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Adenocarcinoma Of The Gastroesophageal Junction Overview 8
  • Therapeutics Development 9
  • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 9
  • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 10
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 11
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes 13
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14
  • Late Stage Products 14
  • Clinical Stage Products 15
  • Early Stage Products 16
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes 20
  • Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 21
  • AB Science SA 21
  • AbbVie Inc 22
  • Advenchen Laboratories, LLC 23
  • Amgen Inc. 24
  • ArQule, Inc. 25
  • AstraZeneca Plc 26
  • Boehringer Ingelheim GmbH 27
  • Boston Biomedical, Inc. 28
  • Bristol-Myers Squibb Company 29
  • Cerulean Pharma, Inc. 30
  • Daiichi Sankyo Company, Limited 31
  • Dr. Reddy's Laboratories Limited 32
  • Eli Lilly and Company 33
  • F. Hoffmann-La Roche Ltd. 34
  • Ganymed Pharmaceuticals AG 35
  • Genentech Inc 36
  • Gilead Sciences, Inc. 37
  • Hutchison MediPharma Limited 38
  • Imugene Limited 39
  • Mebiopharm Co., Ltd. 40
  • MedImmune LLC 41
  • Merck & Co., Inc. 42
  • Merck KGaA 43
  • Millennium Pharmaceuticals Inc 44
  • Neopharm Ltd. 45
  • Novartis AG 46
  • Oncobiologics, Inc. 47
  • Panacea Biotec Limited 48
  • Sanofi 49
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 50
  • Assessment by Monotherapy Products 50
  • Assessment by Combination Products 51
  • Assessment by Target 52
  • Assessment by Mechanism of Action 55
  • Assessment by Route of Administration 58
  • Assessment by Molecule Type 60
  • Drug Profiles 62
  • AL-3818 - Drug Profile 62
  • alpelisib - Drug Profile 64
  • AMG-337 - Drug Profile 67
  • atezolizumab - Drug Profile 69
  • avelumab - Drug Profile 83
  • AZD-4547 - Drug Profile 94
  • AZD-6738 - Drug Profile 96
  • BI-853520 - Drug Profile 97
  • cabazitaxel - Drug Profile 98
  • catumaxomab - Drug Profile 100
  • Cellular Immunotherapy for Oncology - Drug Profile 102
  • ceritinib - Drug Profile 103
  • CRLX-101 - Drug Profile 108
  • DS-8201 - Drug Profile 119
  • durvalumab - Drug Profile 120
  • durvalumab + tremelimumab - Drug Profile 131
  • emibetuzumab - Drug Profile 135
  • GS-5745 - Drug Profile 137
  • ibrutinib - Drug Profile 139
  • IMAB-362 - Drug Profile 165
  • IMU-131 - Drug Profile 167
  • ipatasertib - Drug Profile 171
  • ipilimumab - Drug Profile 173
  • JS-001 - Drug Profile 182
  • LAG-525 - Drug Profile 183
  • LY-3127804 - Drug Profile 184
  • masitinib - Drug Profile 185
  • merestinib - Drug Profile 199
  • napabucasin - Drug Profile 201
  • nimotuzumab - Drug Profile 208
  • oxaliplatin - Drug Profile 212
  • panitumumab - Drug Profile 214
  • PDR-001 - Drug Profile 219
  • pembrolizumab - Drug Profile 221
  • pertuzumab - Drug Profile 258
  • ramucirumab - Drug Profile 264
  • SAR-408701 - Drug Profile 274
  • savolitinib - Drug Profile 275
  • serabelisib - Drug Profile 279
  • sonidegib phosphate - Drug Profile 281
  • tivantinib - Drug Profile 285
  • trastuzumab biosimilar - Drug Profile 291
  • trastuzumab biosimilar - Drug Profile 293
  • trastuzumab biosimilar - Drug Profile 294
  • trastuzumab biosimilar - Drug Profile 295
  • trastuzumab biosimilar - Drug Profile 296
  • tremelimumab - Drug Profile 297
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 300
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 302
  • Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 303
  • Featured News & Press Releases 303
  • Appendix 316
  • Methodology 316
  • Coverage 316
  • Secondary Research 316
  • Primary Research 316
  • Expert Panel Validation 316
  • Contact Us 316
  • Disclaimer 317

List of Tables

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 15
  • Number of Products under Investigation by Universities/Institutes, H2 2016 16
  • Comparative Analysis by Late Stage Development, H2 2016 17
  • Comparative Analysis by Clinical Stage Development, H2 2016 18
  • Comparative Analysis by Early Stage Development, H2 2016 19
  • Products under Development by Companies, H2 2016 20
  • Products under Development by Companies, H2 2016 (Contd..1) 21
  • Products under Development by Companies, H2 2016 (Contd..2) 22
  • Products under Investigation by Universities/Institutes, H2 2016 23
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016 24
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016 25
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016 26
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016 27
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016 28
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016 29
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016 30
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016 31
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016 32
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016 33
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 35
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016 36
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 38
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016 39
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016 40
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016 41
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016 42
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016 43
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016 44
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016 45
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016 46
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 47
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016 48
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016 49
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016 50
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016 51
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016 52
  • Assessment by Monotherapy Products, H2 2016 53
  • Assessment by Combination Products, H2 2016 54
  • Number of Products by Stage and Target, H2 2016 56
  • Number of Products by Stage and Mechanism of Action, H2 2016 59
  • Number of Products by Stage and Route of Administration, H2 2016 62
  • Number of Products by Stage and Molecule Type, H2 2016 64
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016 303
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016 304
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016 305

List of Figures

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Comparative Analysis by Clinical Stage Development, H2 2016 18
  • Assessment by Monotherapy Products, H2 2016 53
  • Number of Products by Top 10 Targets, H2 2016 55
  • Number of Products by Stage and Top 10 Targets, H2 2016 55
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 58
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 58
  • Number of Products by Routes of Administration, H2 2016 61
  • Number of Products by Stage and Routes of Administration, H2 2016 61
  • Number of Products by Molecule Types, H2 2016 63
  • Number of Products by Stage and Molecule Types, H2 2016 63
Back to Top